p-chloro-o-toluidine hydrochloride: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 18487 |
CHEMBL ID | 3182298 |
SCHEMBL ID | 131186 |
MeSH ID | M0555395 |
Synonym |
---|
azogene fast red tr |
4-chloro-o-toluidine.hcl |
c.i. 37085 |
nsc7629 |
devol red k |
devol red ta salt |
fast red salt tra |
fast red salt tr |
devol red tr |
nsc-7629 |
kromon green b |
4-chloro-2-methylaniline hydrochloride |
fast red 5ct salt |
azoic diazo component 11 base |
brentamine fast red tr salt |
azanil red salt trd |
4-chloro-2-methylbenzenamine hydrochloride |
3165-93-3 |
c.i. azoic diazo component 11 |
4-chloro-o-toluidine hydrochloride |
hindasol red tr salt |
fast red tr salt |
p-chloro-o-toluidine hydrochloride |
red trs salt |
neutrosel red trva |
4-chloro-o-toluidine (nh2=1) hydrochloride |
red salt ciba ix |
red salt irga ix |
amarthol fast red tr salt |
4-chloro-6-methylaniline hydrochloride |
5-chloro-2-aminotoluene hydrochloride |
2-amino-5-chlorotoluene hydrochloride |
azoene fast red tr salt |
nci-c02368 |
natasol fast red tr salt |
diazo fast red tr |
4-chloro-o-toluidine (nh2=1) |
daito red salt tr |
fast red salt trn |
2-methyl-4-chloroaniline hydrochloride |
wln: zr dg b1 &gh |
chlorhydrate de 4-chloroorthotoluidine |
4-chloro-2-toluidine hydrochloride |
ofna-perl salt rra |
sanyo fast red salt tr |
ci azoic diazo component 11 |
nsc 7629 |
o-toluidine, 4-chloro-, hydrochloride |
un1579 |
chlorhydrate de 4-chloroorthotoluidine [french] |
amarthol fast red tr |
rcra waste number u049 |
asymmetric meta-chloro-ortho-toluidine hydrochloride |
clorhidrato de 4-cloro-o-toluidine |
rcra waste no. u049 |
ccris 153 |
benzenamine, 4-chloro-2-methyl-, hydrochloride |
hsdb 6191 |
chlorhydrate de chloro-4 o-toluidine |
einecs 221-627-8 |
4-chloro-o-toluidinium chloride |
4-chloro-o-toluidine hydrochloride [un1579] [poison] |
unii-1y82dn556p |
1y82dn556p , |
benzenamine, 4-chloro-2-methyl-, hydrochloride (1:1) |
4-chloro-o-toluidine hcl |
cas-3165-93-3 |
NCGC00256591-01 |
tox21_302920 |
dtxcid20288 |
dtxsid0020288 , |
NCGC00258835-01 |
tox21_201283 |
FT-0618236 |
4-chloro-o-toluidine hydrochloride [hsdb] |
SCHEMBL131186 |
2 -amino-5 -chlorotoluene hydrochloride |
VKYZDCTWJGBFDW-UHFFFAOYSA-N |
AKOS016846210 |
CHEMBL3182298 |
4-chloro-2-methylaniline hydrochloride, aldrichcpr |
J-018507 |
Q27253163 |
4-chloro-2-methylaniline;hydrochloride |
D89231 |
4-chloro-o-toluidinehydrochloride |
Excerpt | Relevance | Reference |
---|---|---|
" 4-CloT was administered orally over 28 consecutive days (days 1-28), followed by a 28-day treatment-free (days 29-56), and a second dosing phase of 3 days (days 57-59)." | ( DNA Damage Response of 4-Chloro-Ortho-Toluidine in Various Rat Tissues. Christen, F; Funk, J; Guérard, M; Marchand, C; Winter, M; Zeller, A, 2018) | 0.48 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 40.8562 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 53.6069 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 76.7209 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 22.9752 | 0.0015 | 30.6073 | 15,848.9004 | AID1259401 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 4.3647 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 21.8751 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 29.7011 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 60.4918 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (28.57) | 18.7374 |
1990's | 8 (38.10) | 18.2507 |
2000's | 4 (19.05) | 29.6817 |
2010's | 3 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.32) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (12.50%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |